Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated August 08, 2016 titled "Zydus strengthens its derma portfolio with the brand acquisition of MELGAIN from Issar Pharma in India." Buy Cadila Healthcare Ltd., target Rs 440.0 : Citigroup
Citigroup sees limited scope for further deterioration in Cadilla Healthcare financials. Updates
On June 20, 2016, the Company had announced the acquisition of two ANDAs from Teva that were being divested by Teva as a pre-condition to its acquisition of Allergan's generic business. The acquisition of these ANDAs was contingent on the closing of the Teva-Allergan Generics transaction and approval by the US Federal Trade Commission.Cadila Healthcare Ltd has now informed BSE that the transaction has now been completed and these ANDAs have... Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Cadila Healthcare Ltd has informed BSE regarding the details of Voting results at the 21st Annual General Meeting (AGM) of the Company held on August 03, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report. Outcome of AGM
Cadila Healthcare Ltd has informed BSE that the 21st Annual General Meeting (AGM) of the Company was held on August 03, 2016. Cadila Healthcare Q1 net dips 23% to Rs 356 crore
Shares of the company closed at Rs 347 on BSE, down 0.22% from the previous close Announces Q1 (Standalone & Consolidated) results & Limited Review Report (Standalone & Consolidated) for the Quarter ended June 30, 2016
Cadila Healthcare Ltd has announced the following results for the quarter ended June 30, 2016:The Unaudited Standalone results for the Quarter ended June 30, 2016The Company has posted a net profit of Rs. 1651 million for the quarter ended June 30, 2016 as compared to Rs. 5650 million for the quarter ended June 30, 2015. Total Income has decreased from Rs. 19329 million for the quarter ended June 30, 2015 to Rs. 13155 million for the quarter ended June 30, 2016.... Post results conference call with investors / analysts
Cadila Healthcare Ltd has informed BSE regarding "Post results conference call with investors / analysts". Updates
Cadila Healthcare Ltd has informed BSE that Company's US based 100% subsidiary company Zydus Pharmaceuticals (USA) Inc. (Zydus) will begin informing on July 12, 2016 its customers that Zydus will start selling an authorized generic of Asacol HD (mesalamine delayed - release tablets 800 mg) in the United States commencing on August 01, 2016. Overweight Cadila Healthcare Ltd., target Rs 399 : Morgan Stanley
Morgan Stanley estimates that Cadila can generate up to $35 million upside and could generate over 90 per cent in PBT margins